The company believes its apheresis-based device can enhance emerging liquid biopsy methods, allowing them to detect cancer DNA fragments in larger numbers of individuals.
These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.
US Appeals Court Overturns Roche Win in Illumina NIPT Suit
The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.
The Stanford University spinout claims it can get three times the nucleic acid yield as column- or magnetic bead-based methods, with less damage to the molecules.
Illumina Seeks Preliminary Injunction Against BGI in US Patent Infringement Case
BGI is planning to offer free trials of its MGI DNBSEQ-G400 sequencing system to key opinion leaders, a development Illumina is trying to stop.